Factors influencing treatment recommendations in node-negative breast cancer

Journal of Oncology Practice

Volumn 7, Issue 1, 2011, Pages 26-30

  Elder, By Elisabeth Edstrom ^a,b   Hay, Sally Baron ^a   Moore, Katrina ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTROLLED STUDY; HOSPITAL; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 79955684236     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2010.000024     Document Type: Article

References (18)

1. Goldhirsch A, Ingle JN, Gelber RD, et al: Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329, 2009
2. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. http://www.nccn.org
3. National Breast and Ovarian Cancer Centre: Clinical Practice Guidelines for the Management of Early Breast Cancer. http://www.nbocc.org.au
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
5. Adjuvant! Online: Decision making tools for health care professionals. http:// www.adjuvantonline.com
6. Hassett MJ, Hughes ME, Niland JC, et al: Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer. J Clin Oncol 26:5553-5560, 2008
7. American Joint Committee on Cancer: AJCC Cancer Staging Manual (ed 6). New York, Springer, 2002
8. Cancer Institute NSW: Treatment Protocols, Breast Cancer. http://www.eviq. org.au
9. Jatoi I, Hilsenbeck SG, Clark GM, et al: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17:2334-2340, 1999 (Pubitemid 29368231)
10. Epstein RJ, Leung TW, Mak J, et al: Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center. Cancer Invest 24:367-373, 2006 (Pubitemid 43932680)
11. de Boer M, van Deurzen CH, van Dijck JA, et al: Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 361:653-663, 2009
12. Gonzalez-Angulo AM, Litton JK, Broglio KR, et al: High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27: 700-706, 2009
13. Viani GA, Afonso SL, Stefano EJ, et al: Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: A meta-analysis of published randomized trials. BMC Cancer 7:153, 2007
14. Duric V, Stockler M: Patients' preferences for adjuvant chemotherapy in early breast cancer: A review of what makes it worthwhile. Lancet Oncol 2:691-697, 2001 (Pubitemid 33085815)
15. Jansen SJ, Kievit J, Nooij MA, et al: Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? Br J Cancer 84:1577-1585, 2001 (Pubitemid 32612486)
16. Thewes B, Meiser B, Duric VM, et al: What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile? Lancet Oncol 6:581-588, 2005 (Pubitemid 41051936)
17. Zujewski JA, Kamin L: Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncol 4:603-610, 2008
18. Cardoso F, Van't Veer L, Rutgers E, et al: Clinical application of the 70-gene profile: The MINDACT trial. J Clin Oncol 26:729-735, 2008 (Pubitemid 351264385)